The missing ‘interstitial vasculitis’  by Airoldi, Andrea et al.
early as in 1989, by Coronel et al.3 This effect was also
demonstrated again by our group in 2004 in patients on
peritoneal dialysis (PD) with an angiotensin receptor blocker
(irbesartan); besides the decrease of peritoneal protein leakage
and proteinuria, irbesartan was also shown to induce changes
in other peritoneal membrane functions.4 Both studies are
mentioned by Kolesnyk et al.5 in their recent review as the
ﬁrst studies in PD patients with this approach.
Studies with ACEIs, angiotensin receptor blockers, or other
substances that can modify peritoneal transport and maybe
improve technique survival still are needed, but we wish to
point out our modest contribution.
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The Authors Reply: We thank Dr Coronel for his
comments.1 Indeed, over two decades ago, Coronel et al.2
examined the effects of blockade of the renin–angiotensin–
aldosterone system (RAAS) on peritoneal membrane function.
Although the two studies mentioned were both small with
a short exposure time to RAAS blocking agents,2,3 they were
the earliest studies to report the effect of blocking the RAAS
on peritoneal membrane function in peritoneal dialysis
patients, setting the stage for the subsequent, larger-scale
observational studies by Kolesnyk et al.4,5 Unfortunately, we
were limited in the number of references for this mini-review,
and did not have the opportunity to discuss these smaller
early studies.
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The missing ‘interstitial vasculitis’
To the Editor: In a recent review on acute interstitial
nephritis (AIN),1 the authors state that AIN may be
associated with systemic disorders such as sarcoidosis,
Sjogren, or systemic lupus erythematosus, but they did not
mention the ‘interstitial vasculitis’, that is, AIN as the only
expression of renal vasculitis.
However, the occurrence of an involvement conﬁned to
the capillaries of renal tubular and interstitial structures in
the setting of systemic vasculitides has been clearly stated in
previous papers published by the European Vasculitis Study
group2 and others.3
Although interstitial vasculitis associated with glomerular
vasculitis is a common observation, interstitial vasculitis as
the only expression of renal involvement in systemic
vasculitides is a rare entity reported in 1% of cases. Pathogenic
mechanisms are presumed to be the same as described in
systemic vasculitis, eventually leading to the destruction of
the capillary walls of peritubular and interstitial capillaries
due to the consequences of inﬂammatory reaction from the
inﬁltrated cells.
However, the most intriguing point is the unknown
reasons for which the occurrence of this kind of vasculitis
only conﬁned to the tubular and interstitial capillary walls is
so rare an event. Some reports of the literature3,4 and our
personal experience in one case might suggest the existence
of a speciﬁc nosographic entity characterized by the co-
existence of giant cell (temporal) arteritis, polymyalgia
rheumatica, and renal interstitial vasculitis. Therefore, we
Table 1 | Etiology of biopsy-proven acute interstitial nephritis
(modified from Praga and Gonza´lez1)
Drugs Antibiotics, NSAIDs, acyclovir, allopurinol,
furosemide, omeprazole, etc.
Infections Bacteria, viruses, others
Associated with
systemic diseases
Sarcoidosis, Sjogren, systemic lupus
erythematosus, vasculitis
Idiopathic Anti-TBM, etc.
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suggest a modiﬁed version of the previously published
Table 11 underscoring the existence of this very interesting
pattern (Table 1).
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The Authors Reply: We appreciate the interest of Airoldi
et al.1 in our review ‘Acute interstitial nephritis’.2 The
uncommon clinical cases on which they comment (interstitial
vasculitis without glomerular involvement) have a great
clinical and pathogenic interest. However, their inclusion as
another type of acute interstitial nephritis (AIN) is, in our
opinion, debatable. AIN is usually deﬁned as a syndrome with
different etiologies and is characterized by the presence of
inﬂammatory inﬁltrates and edema within the interstitium,
whereas glomeruli and vessels are distinctly normal.2,3
This deﬁnition is useful to distinguish true AIN from those
interstitial inﬁltrates and edema that very frequently accom-
pany many forms of glomerulonephritis and vasculitis. For
instance, in the study of Hauer et al.,4 interstitial inﬁltrates
were found in 92% of 173 patients with antineutrophil
cytoplasmic antibody–associated vasculitis. The distinction
between true AIN and interstitial inﬂammation accompany-
ing other renal diseases (glomerulonephritis, vasculitis, and
acute tubular necrosis), although difﬁcult to establish in
some cases, is convenient not only for academic purposes:
prognosis and treatment of these entities is very different. For
all these reasons, we would prefer ‘interstitial vasculitis’ as the
most appropriate and precise diagnosis for the patients
reported by Airoldi et al. To be included among the different
causes of AIN, they could be classiﬁed within a subgroup
of ‘interstitial nephritis accompanying glomerulonephritis
and vasculitis’.
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Corin: a serine protease
To The Editor:We read with great interest the commentary in
a recent issue of Kidney International, in which Klein1
provided an insightful discussion on potential roles of corin
and atrial natriuretic peptide (ANP) in regulating sodium
reabsorption in nephrotic syndrome.2 In this article, however,
corin was indicated as a ‘serine/threonine’ protease.1 Unlike
serine/threonine protein kinases, which phosphorylate the OH
group of serine or threonine residues, corin is a serine protease,
that is, proteolytic enzyme that cleaves peptide bonds within a
polypeptide.3 The catalytic activity of corin is mediated by a
reactive Ser residue that is part of the catalytic triad (Asp, His,
and Ser) in its protease domain (Figure 1). As a trypsin-like
serine protease, corin has a substrate speciﬁcity favoring Arg or
Figure 1 |A molecular model of the corin protease domain.
The protease domain of corin is shown in a three-dimensional
structure similar to that of chymotrypsin. b-Sheets and a-helices
are shown in yellow and red, respectively. The catalytic residues
Asp, His, and Ser are shown in purple.
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